In addition, as STING and cGAS expression levels can vary substantially among human tumor types (64,65) and the human STING gene has allelic haplotypes encoding for protein variants with reduced activity (66,67), G4 binder immunomodulation potency can likely vary among different cancer types and patients. This evidence concerns the gene STING1 and neoplasm.